Scarica l'app Stockscreener
99.12
0.49%
0.48
Dopo l'orario di chiusura:
99.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Jefferies highlights Revolution Medicines, Inc. (RVMD)’s RAS(ON) platform in coverage initiation - MSN
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
Revolution Medicines, Inc. (RVMD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revolution Medicines, Inc. (RVMD) stock price, news, quote and history - Yahoo Finance Singapore
Revolution Medicines begins phase 3 pancreatic cancer trial By Investing.com - Investing.com India
Revolution Medicines, Inc. (RVMDW) stock price, news, quote and history - Yahoo Finance Singapore
Revolution Medicines (RVMD) Begins Phase 3 Trial for Pancreatic Cancer Drug - GuruFocus
Wells Fargo Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $144 - Moomoo
Revolution Medicines begins phase 3 pancreatic cancer trial - Investing.com
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer - The Manila Times
Revolution Medicines Begins Treating Patients in Phase 3 - GlobeNewswire
Tema Etfs LLC Decreases Position in Revolution Medicines, Inc. $RVMD - MarketBeat
A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum - Yahoo Finance
Piper Sandler Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Behavioral Patterns of RVMD and Institutional Flows - Stock Traders Daily
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines' Readout of Trial for Pancreatic Cancer Drug Likely Positive, Oppenheimer Says - MarketScreener
Jefferies Highlights Revolution Medicines, Inc. (RVMD)’s RAS(ON) Platform in Coverage Initiation - Insider Monkey
Revolution Medicines (RVMD) price target increased by 10.02% to 136.84 - MSN
Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now? - Insider Monkey
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Revolution Medicines (RVMD) down 8.8% since last earnings report: Can it rebound? - MSN
Revolution Medicines (RVMD) Stock: Executive Sells $3.5M While Wall Street Upgrades to Strong-Buy - mexc.co
Revolution Medicines (RVMD) Stock Dips as Exec Sells $3.5M — But Analysts Aren’t Flinching - mexc.co
Vanguard (RVMD) files amendment showing 0 shares of Revolution Medicines - Stock Titan
Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Revolution Medicines (RVMD) Stock Dips as Exec Sells $3.5M — But Analysts Aren't Flinching - CoinCentral
Revolution Medicines exec Mancini sells $3.5m in shares - Investing.com
Revolution Medicines exec Mancini sells $3.5m in shares By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) officer exercises options, sells 37,450 shares under 10b5-1 plan - Stock Titan
Anthony Mancini of Revolution Medicines (RVMD) details stock options and RSUs - Stock Titan
Revolution Medicines (RVMD) CDO details initial option and RSU stake - Stock Titan
Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy - MSN
Revolution Medicines (NASDAQ:RVMD) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
[144] Revolution Medicines, Inc. SEC Filing - Stock Titan
MIL:1RVMD PB Ratio: 12.09 — 225% Above Median - GuruFocus
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
Wedbush Reiterates Revolution Medicines (RVMD) Outperform Recommendation - MSN
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $427,962.96 in Stock - Defense World
Revolution Medicines (NASDAQ:RVMD) CFO Sells $273,868.44 in Stock - Defense World
(RVMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Revolution Medicines, Inc.: Fundamental Analysis and Financial Ratings | 1RVMD | US76155X1000 - marketscreener.com
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating - MSN
A Look At Revolution Medicines (RVMD) Valuation After AACR RAS(ON) Pipeline Data Catalyst - simplywall.st
Revolution Medicines COO Horn sells $455,918 in shares By Investing.com - Investing.com South Africa
Revolution Medicines Eyes Guidance with Mixed Signals from Financial Reports - timothysykes.com
Revolution Medicines rises on daraxonrasib data that supports phase 3 program - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
1.76%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):